"Biotech CEO Presents 'Strategic Pivot' PowerPoint, Just Admits They're Starting Over From Scratch"

Sutro Biopharma, Inc. (STRO) presented at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 2:15 PM EST, with CEO Jane Chung and Vice President of Clinical Development Jonathan Fawcett participating in the discussion. The presentation, led by Jane Chung, who has been CEO since March 2025, highlighted the company's strategic pivot and transformation into a clinical oncology company, which involved redefining its strategy, rightsizing its team, and extending its runway. As part of this transformation, Sutro has accelerated its pipeline, with its first program, a tissue factor ADC, entering the clinic within just six months of the strategic pivot, and several more programs expected to enter the clinic this and next year. According to Jane Chung, Sutro's mission is to "deliver the next generation of ADCs to drive value today as well as shaping the future of the ADC field" using its differentiated ADC technology, which enables the company to "uniquely optimize every component of an ADC" to create highly effective medicines. With its new strategy in place, Sutro aims to make a significant impact in the field of oncology, and its presentation at the J.P. Morgan Healthcare Conference marked an important milestone in the company's journey towards achieving its goals.